Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

Christopher Schutt; Klaus Bumm; Leonardo Mirandola; Giovanni Bernardini; Nicholas D. Cunha; Lukman Tijani; Diane Nguyen; Joehassin Cordero; Marjorie R. Jenkins; Everardo Cobos; W. Martin Kast; Maurizio Chiriva-Internati

doi:10.3109/08830185.2011.637253

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

Christopher Schutt, Klaus Bumm, Leonardo Mirandola, Giovanni Bernardini, Nicholas D. Cunha, Lukman Tijani, Diane Nguyen, Joehassin Cordero, Marjorie R. Jenkins, Everardo Cobos, W. Martin Kast, Maurizio Chiriva-Internati

Internal Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

Original language	English (US)
Pages (from-to)	22-42
Number of pages	21
Journal	International Reviews of Immunology
Volume	31
Issue number	1
DOIs	https://doi.org/10.3109/08830185.2011.637253
State	Published - Feb 2012

Keywords

CRT
Cancer vaccines
EGFR
HNSCC
HPV

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.3109/08830185.2011.637253

Fingerprint Dive into the research topics of 'Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this

Schutt, C., Bumm, K., Mirandola, L., Bernardini, G., Cunha, N. D., Tijani, L., Nguyen, D., Cordero, J., Jenkins, M. R., Cobos, E., Kast, W. M., & Chiriva-Internati, M. (2012). Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. International Reviews of Immunology, 31(1), 22-42. https://doi.org/10.3109/08830185.2011.637253

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. / Schutt, Christopher; Bumm, Klaus; Mirandola, Leonardo; Bernardini, Giovanni; Cunha, Nicholas D.; Tijani, Lukman; Nguyen, Diane; Cordero, Joehassin; Jenkins, Marjorie R.; Cobos, Everardo; Kast, W. Martin; Chiriva-Internati, Maurizio.

In: International Reviews of Immunology, Vol. 31, No. 1, 02.2012, p. 22-42.

Research output: Contribution to journal › Article › peer-review

Schutt, Christopher ; Bumm, Klaus ; Mirandola, Leonardo ; Bernardini, Giovanni ; Cunha, Nicholas D. ; Tijani, Lukman ; Nguyen, Diane ; Cordero, Joehassin ; Jenkins, Marjorie R. ; Cobos, Everardo ; Kast, W. Martin ; Chiriva-Internati, Maurizio. / Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. In: International Reviews of Immunology. 2012 ; Vol. 31, No. 1. pp. 22-42.

@article{f022fadaede64da7b196ef38c2943578,

title = "Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma",

abstract = "Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.",

keywords = "CRT, Cancer vaccines, EGFR, HNSCC, HPV",

author = "Christopher Schutt and Klaus Bumm and Leonardo Mirandola and Giovanni Bernardini and Cunha, {Nicholas D.} and Lukman Tijani and Diane Nguyen and Joehassin Cordero and Jenkins, {Marjorie R.} and Everardo Cobos and Kast, {W. Martin} and Maurizio Chiriva-Internati",

year = "2012",

month = feb,

doi = "10.3109/08830185.2011.637253",

language = "English (US)",

volume = "31",

pages = "22--42",

journal = "International Reviews of Immunology",

issn = "0883-0185",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

AU - Schutt, Christopher

AU - Bumm, Klaus

AU - Mirandola, Leonardo

AU - Bernardini, Giovanni

AU - Cunha, Nicholas D.

AU - Tijani, Lukman

AU - Nguyen, Diane

AU - Cordero, Joehassin

AU - Jenkins, Marjorie R.

AU - Cobos, Everardo

AU - Kast, W. Martin

AU - Chiriva-Internati, Maurizio

PY - 2012/2

Y1 - 2012/2

N2 - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

AB - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

KW - CRT

KW - Cancer vaccines

KW - EGFR

KW - HNSCC

KW - HPV

UR - http://www.scopus.com/inward/record.url?scp=84856082393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856082393&partnerID=8YFLogxK

U2 - 10.3109/08830185.2011.637253

DO - 10.3109/08830185.2011.637253

M3 - Article

C2 - 22251006

AN - SCOPUS:84856082393

VL - 31

SP - 22

EP - 42

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 1

ER -